Jade Biosciences' Upcoming Conference Participation
Jade Biosciences, Inc. (NASDAQ: JBIO), a notable player in biotechnology, is making waves as it prepares to participate in several significant upcoming conferences. This biotechnology company is dedicated to developing top-tier therapies for autoimmune diseases, and these events present a prime opportunity for sharing their advancements and insights with the healthcare community and potential investors.
Events Schedule
Jade will be featured in the following conferences:
Cantor Global Healthcare Conference
This event is scheduled from September 3rd to 5th, and Jade will host a fireside chat on Tuesday, September 3rd at 3:20 p.m. ET. This will allow the management team to showcase their latest innovations and address any investor inquiries.
Stifel Virtual Immunology and Inflammation Forum
The Stifel event will take place on September 15th and 16th. Jade's fireside chat is set for September 16th at 1:00 p.m. ET, providing another platform for the company to engage with the investment community during discussions centered on immunology and inflammation.
World Medical Innovation Forum
Jade will also participate in the 11th Annual World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham, occurring from September 15th to 17th. A panel discussion titled "Immunology – Creating the Next Blockbuster in I&I" is scheduled for September 16th at 4:40 p.m. ET, where Jade’s leadership will dive deep into the future of immunology treatments.
One-on-One Investor Meetings
Beyond these insightful panels and discussions, members of the Jade management team will engage in one-on-one investor meetings throughout these conferences. This personal interaction fosters deeper connections and allows for tailored conversations about Jade’s innovative pipeline and strategic vision.
Live Webcast Opportunities
Investors interested in the discussions can access a live webcast of both the Cantor and Stifel fireside chats via the Events & Presentations page on the Jade Biosciences website. Additionally, these events will be recorded and archived, available for replays for 90 days after the conclusion of the conferences. This approach ensures all interested stakeholders can stay informed, regardless of their ability to attend live.
About Jade Biosciences
Founded with a vision to address critical unmet needs in autoimmune diseases, Jade Biosciences is actively developing cutting-edge therapies. Among their lead candidates is JADE101, which targets the cytokine APRIL intended for treating immunoglobulin A nephropathy. Moreover, the company is advancing its second development candidate, JADE201, alongside an undisclosed antibody discovery program known as JADE-003, which are currently in preclinical development. Jade's inception stems from innovative assets licensed from Paragon Therapeutics, an antibody discovery engine previously developed by Fairmount.
Contact Information
For further outreach, please contact Jade Biosciences:
Priyanka Shah
Email: Media@JadeBiosciences.com
Investor Relations: IR@JadeBiosciences.com
Phone: 908-447-6134
Frequently Asked Questions
What is the primary focus of Jade Biosciences?
Jade Biosciences focuses on developing innovative therapies for autoimmune diseases.
What conferences is Jade participating in?
Jade is participating in the Cantor Global Healthcare Conference, Stifel Virtual Immunology and Inflammation Forum, and the World Medical Innovation Forum.
How can I watch the live webcasts of the events?
The live webcasts of the events can be found on Jade Biosciences' Events & Presentations webpage.
Who can I contact for more information?
You can contact Priyanka Shah at Jade Biosciences for media and investor inquiries.
What are some of Jade’s lead products?
Jade’s lead products include JADE101 and JADE201, with ongoing development in autoimmune therapeutics.